购物车

全部删除
您的购物车当前为空

IL-17A Protein, Cynomolgus, Recombinant (His)

一键复制产品信息

IL-17A Protein, Cynomolgus, Recombinant (His)

产品编号 TMPJ-01444

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

IL-17A Protein, Cynomolgus, Recombinant (His)

一键复制产品信息

产品编号 TMPJ-01444

规格	价格	库存
5 μg	¥ 479	6-8日内发货
10 μg	¥ 780	6-8日内发货
20 μg	¥ 1,230	5日内发货
50 μg	¥ 2,360	5日内发货
100 μg	¥ 3,960	5日内发货
200 μg	¥ 6,690	5日内发货
500 μg	¥ 13,300	5日内发货
1 mg	¥ 20,100	5日内发货

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

资源下载

重组蛋白用户指南

产品信息

生物活性	1. Loaded Biotinylated Human IL-17RA-Fc on Pro A Biosensor, can bind Cynomolgus IL-17A-His with an affinity constant of 0.33 nM as determined in BLI assay. (Regularly tested) 2. Immobilized Cynomolgus IL-17A-His at 2μg/ml (100 μl/well)can bind Anti-Human IL-17A mAb. The ED50 of Anti-Human IL-17A mAb is 0.128 ug/ml. (Regularly tested)
产品描述	Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.
种属	Cynomolgus
表达系统	HEK293 Cells
标签	C-6xHis
蛋白编号	A0A2K5TTB0
别名	Interleukin-17A,IL-17A,IL17A,IL-17,IL17,Cytotoxic T-Lymphocyte-Associated Antigen 8,CTLA-8,CTLA8
氨基酸序列	Gly24Ala155
蛋白构建	Gly24-Ala155
蛋白纯度	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
分子量	15-25 KDa (reducing condition)
内毒素	< 0.1 ng/µg (1 EU/µg) as determined by LAL test.
缓冲液	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4.
复溶方法	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
存储	Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.